Timing of biologic prophylaxis and postoperative recurrence in Crohn’s disease: A real-life cohort study using propensity score weighting
Clicks: 2
ID: 319942
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #80 of 85 articles by views in inflammatory bowel diseases
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Postoperative recurrence is a major challenge in the management of Crohn’s disease after ileocolonic resection. Although international guidelines recommend early initiation of biologic prophylaxis, the optimal timing remains uncertain in real-world practice. Methods We conducted a retrospective cohort study of Crohn’s disease patients undergoing ileocolonic resection. All patients received biologic prophylaxis within 16 weeks after surgery. Patients were stratified into 3 timing groups: <8 weeks, 8 to 12 weeks, and >12 and ≤16 weeks. To account for baseline differences, a propensity score–based inverse probability of treatment weighting approach was applied. The primary outcome was endoscopic recurrence (ER) at 6 to 12 months. Results Among 173 patients, 79 (46%) initiated biologic prophylaxis within 8 weeks after surgery, 32 (18%) between 8 and 12 weeks, and 62 (36%) between >12 and ≤16 weeks. ER at 6 to 12 months occurred in 103 (59.5%) patients. In the inverse probability of treatment weighting–weighted analysis, initiation of biologic therapy more than 12 weeks after surgery was associated with a significantly higher risk of ER compared with initiation within 8 weeks (risk ratio, 1.96; 95% confidence interval, 1.45-2.65; P < .001), whereas no significant difference was observed between initiation within 8 weeks and 8-12 weeks (risk ratio, 1.44; 95% confidence interval, 0.93-2.23; P = .10). In multivariable logistic regression analysis, smoking, prior intestinal resections, and delayed initiation of biologic prophylaxis were independently associated with ER. Conclusions In half of patients, prophylactic biologic therapy was initiated more than 8 weeks after ileocolonic resection. Initiation of biologic prophylaxis beyond 12 weeks after surgery was associated with a significantly increased risk of ER.
| Reference Key |
openalex_W7167737137
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Angelo Del Gaudio, Federica Di Vincenzo, Giuseppe Cuccia, Gaetano Coppola, Lucrezia Laterza, Franco Sacchetti, Paola Caprino, Luigi Sofo, Gabriele Dragoni, E. Foscarini, Francesca Profeta, Elisa Schiavoni, Daniele Napolitano, Antonio Gasbarrini, Daniela Pugliese, A Papa, Loris Riccardo Lopetuso, Franco Scaldaferri |
| Journal | inflammatory bowel diseases |
| Year | 2026 |
| DOI |
10.1093/ibd/izag130
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.